|
| Home : Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference |
|
Nov 08
2021 |
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference |
|
STATEN ISLAND, N.Y., Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/acurx-announces-new-microbiome-data-from-its-phase-2a-clinical-trial-of-ibezapolstat-for-cdi-at-the-9th-international-c-diff-conference-301417335.html |
| |
|
Related News
|
» Food Contact Plastics in a Circular Economy Webinar
» Jacobs Invests in Leading Geospatial Analytics Company HawkEye 360
|
|
|
